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ABSTRACT
A series of antisense oligonucleotides (ASOs)
containing either 20-O-methoxyethylribose (MOE) or
locked nucleic acid (LNA) modifications were de-
signed to investigate whether LNA antisense oligo-
nucleotides (ASOs) have the potential to improve
upon MOE based ASO therapeutics. Some, but not
all, LNA containing oligonucleotides increased
potency for reducing target mRNA in mouse liver up
to 5-fold relative to the corresponding MOE con-
taining ASOs. However, they also showed profound
hepatotoxicity as measured by serum transamina-
ses, organ weights and body weights. This toxicity
was evident for multiple sequences targeting three
different biological targets, as well as in mismatch
control sequences having no known mRNA targets.
Histopathological evaluation of tissues from LNA
treated animals confirmed the hepatocellular
involvement. Toxicity was observed as early as
4 days after a single administration. In contrast, the
corresponding MOE ASOs showed no evidence for
toxicity while maintaining the ability to reduce target
mRNA. These studies suggest that while LNA ASOs
have the potential to improve potency, they impose
a significant risk of hepatotoxicity.
INTRODUCTION
Synthetic oligonucleotides and their analogs are commonly
used as research reagents to modulate gene expression in
cell culture and in animal models. The most broadly utilized
mechanism by which oligonucleotides are exploited for
modulation of gene expression is through binding of the anti-
sense oligonucleotide (ASO) to a speciﬁc mRNA or pre-
mRNA by Watson–Crick base pairing. Upon binding, the
oligonucleotide can modulate RNA processing, inhibit trans-
lation or promote degradation. Mechanisms of degradation
include recruitment of RNase H, which cleaves the RNA
strand of a DNA:RNA duplexes, and activation of the RNA
interference (RNAi) pathway utilizing short RNA duplexes
(siRNA) or hairpins (shRNA). In addition to the use of
oligonucleotides as research reagents there is increasing inter-
est in exploiting oligonucleotides as therapeutic agents. Cur-
rently there is one approved antisense product (Vitravene,
fomivirsen) (1) and >30 products in active development.
The ﬁrst generation of ASO therapeutics were 20-DNA
oligomers uniformly modiﬁed with the phosphorothioate
(PS) backbone substitution and work predominantly through
an RNase H-dependent mechanism. The substitution of sulfur
for oxygen in the phosphate ester confers several properties
onto ASOs which are crucial for their use as systemic
drugs (2). Foremost, the PS linkage greatly increases stability
to nucleolytic degradation (3), such that they possess sufﬁ-
cient stability in plasma, tissues and cells to avoid meta-
bolism prior to reaching the target RNA after systemic
administration to an animal. Additionally, the PS modiﬁca-
tion confers a substantial pharmacokinetic beneﬁt by increas-
ing the binding to plasma proteins, which prevents rapid renal
excretion (4). While greatly increasing the stability of ASOs,
PS modiﬁed drugs are still subject to metabolism, and have
tissue half-lives of 1–3 days (4), which is sub-optimal for a
parenterally administered drug. Furthermore, the PS modiﬁ-
cation reduces afﬁnity for the target RNA (the ultimate bio-
logical receptor for ASO drugs) (3), which adversely effects
potency.
In order to improve upon the ﬁrst generation ASO drugs,
many different modiﬁcations to the core nucleoside monomer
unit of the ASO have been evaluated for their effects on afﬁn-
ity for complementary RNA, nuclease resistance and ASO
potency. Most of the modiﬁcations which enhance afﬁnity
and nuclease resistance, in particular the 20-substituted nucleo-
sides, also limit the ability of the ASO to support RNase
H-mediated cleavage of the targeted RNA (5). Efforts to
optimize the design of ASOs to retain the beneﬁcial proper-
ties of 20-modiﬁcations, yet maintain RNase H activity have
led to the development of chimeric oligonucleotide designs
which employ higher afﬁnity 20-substituted nucleosides
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There are several designs for such chimeric oligonucleotides
with ‘gapmer’ designs being most common in which a
central DNA region of 7–14 nt is ﬂanked on the 50 and 30
ends by 2–6 20-modiﬁcations (Figure 1a) (6).
The most advanced second generation antisense designs
are 20-O-methoxyethylribose (7) (MOE) gapmer oligo-
nucleotides (Figure 1). MOE modiﬁed ASOs show increased
afﬁnity toward a complementary RNA, and are highly resis-
tant toward degradation by nucleases (8). These improve-
ments result in a substantial (>20-fold) increase in
oligonucleotide potency in cell culture, relative to ﬁrst gene-
ration ASOs (9,10). In animals, MOE ASOs have been shown
to possess both excellent pharmacokinetic properties (11–13)
and robust pharmacological activity (14,15). Furthermore, the
selective inhibition of gene expression with MOE ASOs
elicits positive pharmacological activity in several animal
models of human disease when given systemically with clini-
cally relevant routes and schedules of administration (15–19).
These beneﬁcial properties have translated to human thera-
peutics. For example, a MOE ASO targeting ApoB has
shown a dose-dependent reduction of target protein con-
current with lowering of LDL cholesterol. Doses as low as
100 mg per week produced statistically signiﬁcant reductions
in ApoB protein, and a dose of 200 mg per week reduced
serum ApoB protein by 50% (20). Furthermore, to date
MOE ASOs have an excellent safety record in human clinical
trials (20–22).
The improvement in potency of MOE ASOs has, in part,
been attributed to the increased afﬁnity for target mRNA con-
ferred by the MOE modiﬁcation. Although MOE provides a
substantial improvement in afﬁnity, bicyclic nucleoside
modiﬁcations such as 20,40-methylene bridged nucleic acids
(23,24) commonly called ‘locked nucleic acid’ (LNA,
Figure 1b) (25,26) have been shown to provide a further
increase in afﬁnity. LNA containing chimeric ASOs are just
entering human clinical trials, and have recently been shown
to inhibit growth in human tumor xenograft models (27).
However, studies of the effects of LNA ASOs versus endoge-
nous targets in liver, a tissue where antisense effects have
been extensively characterized, have not been reported to
date. In order to investigate whether LNA ASOs have the
potential to improve upon MOE based ASO therapeutics,
we directly compared the potency and therapeutic index of
several designs of MOE and LNA containing ASOs in cell
culture and in rodent liver after systemic administration.
Our results indicate that although LNA modiﬁed ASOs have
the potential to improve potency, they impose a signiﬁcant
risk of hepatotoxicity which must be considered when design-
ing LNA containing antisense therapeutics.
MATERIALS AND METHODS
Oligonucleotide design and synthesis
ASOs 1, 3 and 4 (sequence 50-GCTCATACTCGTAGGCCA-
30, position 791–808) and 2 (sequence 50-CTCATACTCGT-
AGGCC-30, position 792–807) are complementary to Mus
musculus TNFRSF1A-associated via death domain (TRADD)
mRNA (Genbank accession no. NM_001033161). The ASO
lead 1a is the murine homolog (a G to A base change at posi-
tion 5) of the human TRADD lead reported previously (28).
Control oligonucleotides 5 (50-GCCCAATCTCGTTAGC-
GA-30) were designed with six mismatches to 4, such that
they contained >4 mismatches to all known mouse sequence.
ASOs 6 and 7 (sequence TCTGGTACATGGAAGTCTGG,
position 8232–8251) and 8 (sequence AAGTTGCCACCCA-
CATTCAG, position 5586–5605) are complementary to Mus
musculus apolipoprotein B (ApoB) mRNA (Genbank acces-
sion no. XM_137955.5). The sequences were identiﬁed by
a screen of 5-10-5 MOE 20mer ASOs as described previously
(29–31). ASOs 9, 10 and 11 (sequence 50-CTGCTAGCCTC-
TGGATTTGA-30, position 1931–1950) are complementary
to M.musculus phosphatase and tensin homolog (PTEN),
mRNA (Genbank accession no. NM_008960). ASO 9 (18)
and control oligonucleotide 12 (19) have been described
previously.
MOE phosphoramidites were prepared as described
previously (7,32,33). LNA and 20-deoxyribonucleoside phos-
phoramidites were purchased from commercial suppliers.
Oligonucleotides were prepared similar to that described pre-
viously (34) on either an Amersham AKTA 10 or AKTA 100
oligonucleotide synthesizer. Modiﬁcations from the reported
procedure include: a decrease in the detritylation time to
 1 min, as this step was closely monitored by UV analysis
for complete release of the trityl group; phosphoramidite con-
centration was 0.1 M; 4,5-dicyanoimidazole catalyst was
used at 0.7 M in the coupling step; 3-picoline was used
instead of pyridine for the sulfurization step, and the time
decreased from 3 to 2 min. The oligonucleotides were then
puriﬁed by ion-exchange chromatography on an AKTA
Explorer and desalted by reverse phase HPLC to yield modi-
ﬁed oligonucleotides in 30–40% isolated yield, based on
the loading of the 30-base onto the solid support. Oligo-
nucleotideswerecharacterizedbyion-pair-HPLC-MSanalysis
(IP-HPLC-MS) with an Agilent 1100 MSD system. The
purity of the oligonucleotides was >90% (Supplementary
Table S1).
Cell culture assays
For determining potency in cell culture, mouse brain endo-
thelial (bEND) cells (American Type Culture Collection)
were transfected with the indicated concentration of oligo-
nucleotide for 4 h using 3 mg/ml Lipofectin in OptiMEM.
Transfection mixes were then replaced with normal growth
Figure 1. (a) Gap design of current generation of ASO therapeutics having
20-modified ‘wings’ at the 30 and 50 ends flanking a central 20-deoxy gap
region. (b) Structures of MOE and LNA nucleosides.
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containing penicillin-streptomycin]. Cells were harvested
24 h later and RNA was puriﬁed using Qiagen 96-well
RNeasy plates. RNA was analyzed for TRADD and
cyclophilin A RNA levels. TRADD RNA levels, normalized
to those of cyclophilin A, are expressed as percent untreated
control (% UTC). Each treatment was performed in triplicate.
IC50 values were determined using GraphPad Prism software
by ﬁtting the data to a sigmoidal dose–response curve (vari-
able slope) using a deﬁned top of 100% and bottom of 0%.
For caspase induction, A549 cells (American Type Culture
Collection), a human lung carcinoma cell line, were seeded
into 96-well plates and transfected the following day with
300 nm ASO for 4 h using Lipofectin (Invitrogen). Transfec-
tion mixes were subsequently replaced with normal growth
media (Ham’s F12K media containing 10% FBS). Cells
were assayed 44 h later for caspase 3 activity and cell number
(CyQuant) as described previously (35).
Animal treatment
All animal experiments were conducted according to the
American Association for the Accreditation of Laboratory
Animal Care guidelines and were approved by the Animal
Welfare Committee. Male Balb/c mice, aged 6–8 weeks,
were obtained from Charles River Laboratories. Compounds
were suspended in phosphate-buffered saline (PBS), ﬁlter
sterilized and administered by intraperitoneal (i.p.) injection
according to the indicated dosing schedules in a volume cor-
responding to 10 ml/g animal weight. Animals were main-
tained at a constant temperature of 23 C and were allowed
standard lab diet and water ad libitum and animal weights
were monitored prior to dosing throughout the live phase of
the study. Immediately prior to sacriﬁce, mice were anes-
thetized with isoﬂurane and terminal bleed was performed
by cardiac puncture. Plasma or serum was isolated from
whole blood and analyzed for clinical chemistries. Alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels were determined using an Olympus AU400e
bioanalyzer. Immediately following terminal blood draw,
mice were sacriﬁced by cervical dislocation while under
anesthesia. In conjunction with necropsy, liver and spleen
weights were determined. Effects of compounds on organ
weights, normalized to body weight, are expressed relative
to those of the saline treated group.
RNA analysis
Tissues were homogenized in 4 M guanidine isothiocyanate,
25 mM EDTA, 50 mM Tris–HCl, pH 6, containing 1 M
b-mercaptoethanol immediately following sacriﬁce and
homogenized. RNA was extracted using RNeasy columns
(Qiagen) according to manufacturer’s protocol. RNA was
eluted from the columns with water. RNA samples were ana-
lyzed by ﬂuorescence-based quantitative RT–PCR using an
Applied Biosystems 7700 sequence detector. Levels of target
RNAs as well as those of cyclophilin A, a housekeeping
gene, were determined. Target RNA levels were normalized
to cyclophilin levels for each RNA sample. Primers used
for determination of TRADD RNA level are as follows:
forward primer (FP) 50-GGCCGCCTGCCAGAC-30, reverse
primer(RP)50-TGAAGAGTCAGTGGCCGGTT-30 andprobe
(PR) 50-6FAM-TTTCTGTTCCACGGGCAGCTCGTAGT-
TAMRA-30. Primers used for determination of PTEN RNA
level are as follows: FP 50-ATGACAATCATGTTGCAGCA-
ATTC-30,R P5 0 CGATGCAATAAATATGCACAAATCA 30
and PR 50-6FAM-CTGTAAAGCTGGAAAGGGACGGACT-
GGT-TAMRA-30. Primers used for determination of ApoB
RNA level are as follows: forward primer (FP) 50-GAAAAT-
AGACTTCCTGAATAACTATGCATT-30, reverse primer (RP)
50-ACTCGCTTGCCAGCTTGC-30 and probe (PR) 50-6FAM-
TTTCTGAGTCCCCGTGCCCAACA-TAMRA-30. Primers
used for determination of cyclophilin A RNA level are as
follows: FP 50-TCGCCGCTTGCTGCA-30,R P5 0-ATCGGCC-
GTGATGTCGA-30 and PR 50-6FAM-CCATGGTCAACCCC-
ACCGTGTTC-TAMRA-30.
Western blot analysis
Frozen tissue samples were homogenized in RIPA buffer
(PBS containing 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) containing Complete  protease inhibitors
(Roche), and protein concentrations were determined by Bio-
Rad protein assay. Protein samples were separated on a 10%
PAGE gel (Invitrogen) and subsequently transferred to a
PVDF membrane (Invitrogen). Membranes were incubated
at room temperature in blocking buffer consisting of 5%
non-fat dry milk in TBS-T for 1 h. Rabbit polyclonal antibod-
ies were obtained from commercial sources, and used at
1:1000 dilution. Phospho-eIF2alpha (Ser51) antibody was
obtained from Cell Signaling Technology (Catalog no.
9721). HRP conjugated anti-rabbit secondary antibodies
were obtained from Jackson ImmunoResearch and were
used at 1:2500 dilution. Protein bands were visualized using
ECL-plus reagent (Amersham).
Capillary gel electrophoresis
Immediately following removal, organs were frozen in liquid
nitrogen and stored at  80 C until ASO extraction. Tissues
were weighed and ASO was extracted as described previously
(12,36). Brieﬂy, tissue samples were homogenized in a
BioSavant (Bio 101), and subjected to solid phase extraction
using a phenyl bonded SPE column (Isolute). Concentrations
of ASO in tissue as well as metabolite proﬁles were deter-
mined by capillary gel electrophoresis (CGE) using a
Beckman P/ACE model 5010 capillary electrophoresis unit.
Hematoxylin and eosin (H&E) staining
Tissue samples were ﬁxed in formalin for a minimum of
1 day followed by incubation in 70% ethanol for a minimum
of 1 day. Tissue samples were further dehydrated and pro-
cessed using a Leica ASP300 tissue processor. Tissues were
embedded in parafﬁn and 4 m sections were mounted on
positive charged glass slides. Deparafﬁnized and rehydrated
samples were stained for hematoxylin and eosin (H&E),
using a Leica Autostainer XL.
Immunohistochemical staining
Immunohistochemical studies were performed to detect the
cleaved form of caspase 3, as well as Bcl2-associated X
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beta (GADD45b) protein. Formalin-ﬁxed, parafﬁn-embedded
tissue sections were mounted on positive charged glass slides.
Deparafﬁnized and rehydrated samples were heated for
20 min at 95 C in citrate buffer solution. The slides were
cooled for 20 min and endogenous peroxidase was blocked
with 3% hydrogen peroxide (H2O2) in methanol for 10 min
at room temperature, followed by rinsing in distilled water.
To detect cleaved caspase 3, Bax and GADD45b, the sections
were incubated 1 h at RT with anti-cleaved caspase 3 poly-
clonal antibody, (1:50 dilution; Cell Signaling Technology,
Danvers, MA), anti-Bax monoclonal rabbit antibody, E63
(1:200 dilution; Epitomics, Burlingame CA) and anti-
GADD45b polyclonal antibody, C18 (0.5 mg/ml; Santa
Cruz, CA), respectively. The HRP conjugated secondary
antibodies were obtained from Jackson ImmunoResearch
Laboratories (1:200 dilution; West Grove, PA). The antigen
was visualized with DAB (Dako Cytomation—Cat3K3466)
for 5 min. For negative controls, primary antibodies were
replaced with isotype matched normal IgG. The slides were
then counterstained with hematoxylin.
RESULTS
Effect of LNA modification in cell culture
To directly compare the effects of LNA and MOE modiﬁ-
cations, we designed a series of oligonucleotides targeting
mouse TRADD mRNA. We have previously published the
identiﬁcation and characterization of MOE modiﬁed oligo-
nucleotides targeting human TRADD, a death domain adapter
protein that interacts with TNF receptor family members
(28). The lead ASO from this study, a 4-10-4 MOE design,
contains a single mismatch to murine TRADD mRNA,
which was corrected to provide the mouse TRADD ASO
1a. Transfection of 1a (Table 1) into bEND cells reduces
TRADD mRNA levels in a concentration-dependent manner
as measured by quantitative RT–PCR (Figure 2 and Table 2),
to give an IC50 of  8 nM. The 4-10-4 LNA version of this
sequence (1b) reduced potency by  4-fold relative to the cor-
responding MOE ASO. Because LNA has an increased afﬁn-
ity relative to MOE, we hypothesized that the shorter ASOs
with reduced LNA content may maintain or improve potency,
and thus prepared the 3-10-3 MOE and LNA ASOs 2a and
Table 1. Oligonucleotide targets, sequences and chemistry
aStructure code is nucleotide units 50 to 30. Capital letter is base code: G ¼ guanine, A ¼ adenine, C ¼ cytosine,
mC ¼ 5-methylcytosine, T ¼ thymine. Small
subscript are sugar and linkage codes: e ¼ MOE sugar, l ¼ LNA sugar, d ¼ deoxyribose sugar, s ¼ PS linkage, o ¼ PO linkage.
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potency, whereas the potency of the 16mer LNA 2b was
improved relative to the 18mer LNA ASO 1b. These results
are consistent with a previous study of LNA ASOs (37), in
which the high afﬁnity of LNA facilitated good target
reduction with 16mer LNA ASO designs.
Since RNase H activity has been found to be an important
factor in antisense potency both in vitro and in vivo (38),
optimization of the gap region is of crucial importance.
Because LNA has been shown to alter the conformation of
adjacent DNA nucleotides for several residues (39), and
duplex conformation is critical for RNase H activity (5), we
included ASOs having increased gap sizes (3 and 4) in our
SAR set. This replacement of high afﬁnity modiﬁcations by
additional 20-deoxy units could increase RNase H activity
by either adding potential cleavage sites, or by reducing the
conformational transmission effects of LNA. We reasoned
that the increased afﬁnity of LNA relative to MOE would com-
pensate for the reduced number of 20-modiﬁcations, and may
increase potency. Replacing two internal MOE modiﬁcations
of 1a with deoxy nucleosides provided the 3-12-3 ASO 3a,
which maintained potency relative to 1a. Further substitution
of two additional MOE residues gave the 2-14-2 ASO 4a,
which reduced potency of 3–4-fold. In contrast, replacing two
LNA units of 1b with deoxy nucleosides resulted in a marked
improvement, with 3b having an IC50 of 1–2 nM. As with the
MOE series, further substitution to afford 4b reduced the
potency, such that the LNA 2-14-2 4b was approximately
equipotent relative to the parent 4-10-4 MOE 1a.A s
expected, both MOE (5a) and LNA (5b) four base mismatch
control ASOs were inactive.
In vivo effects of 20-MOE and LNA modified
oligonucleotides
To determine if the behavior of LNA modiﬁed ASOs was
similar in animals, mice were treated with ASOs at several
dosage levels two times per week for 3 weeks. As expected,
treatment of mice with the 4-10-4 MOE ASO 1a twice per
week reduced TRADD mRNA in liver in a dose-dependent
manner, producing a 77% reduction at the 4.5 mmol/kg
dose ( 30 mg/kg, Figure 3). Doses of mmol per kg were
employed as the compounds were of slightly different
molecular weight, and we wished to directly compare
potency on a molar basis. Consistent with cell culture results,
the corresponding LNA analog 1b was less efﬁcacious at this
dose, resulting in only a 65% inhibition of mRNA. The
potency of this ASO is difﬁcult to assess from the limited
dose–response data, but it appears to have a reduced efﬁcacy,
at least at the doses evaluated. Also consistent with cell cul-
ture results, the MOE 16mer ASO 2a was weakly active,
while the corresponding LNA 2b showed  80 and 60%
reductions in TRADD mRNA at the 4.5 and 1.5 mmol/kg
doses, respectively.
The 3-12-3 and 2-14-2 MOE ASOs 3a and 4a produced a
small increase in potency relative to the 4-10-4 1a, as well as
an increase in efﬁcacy at the 4.5 mmol/kg dose, with 2-14-2
design giving an 89% reduction in mRNA. The LNA ASO
3b (3-12-3 design) showed an increase in potency, achieving
 80% reduction of mRNA at the 1.5 mmol/kg dose. In con-
trast to cell culture results, the 2-14-2 LNA ASO 4b further
improved activity, giving a 75% inhibition of TRADD
Figure 2. Reduction of TRADD mRNA in bEND cells after transfection with
MOE ASO 1a or LNA ASO 1b (top panel) or MOE ASO 4a or LNA ASO 4b
(bottom panel).
Table 2. Activity and liver levels of MOE (a series) and LNA (b series) ASOs
ASO IC50 (nM)
in vitro
a
Est. ED50 (mg/kg)
in vivo
b
Liver conc.
(mg/g tissue) ± SD
c
1a 8.3 13 116 ± 20
2a >60 >25 54 ± 5.9
3a 8.5 11 92 ± 11
4a 27 9 96 ± 14
1b 35 13
2b 15 6 64 ± 6.1
3b 1.6 4 69 ± 4.5
4b 8.4 2 48 ± 8.9
5a  60  25
5b  60  25
aIC50values for reduction of TRADD mRNA in bEND cells after transfection
with Lipofectin.
bED50 values for reduction of TRADD mRNA in mouse liver after dosing
twice weekly for three weeks estimated by interpolation.
cDetermined by capillary gel electrophoresis for the 4.5 mmol/kg dose groups
at end of study.
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Interpolation of the TRADD mRNA reduction data allowed
estimation of a rough ED50, which could be converted to
mg/kg dosing for a comparison of in vivo potency
(Table 2). For 3b, the data suggest an  3-fold increase in
potency over the corresponding MOE 3a and its 4-10-4 par-
ent 1a. The 2-14-2 LNA gapmer design 4b provided an even
larger increase in potency, the magnitude of which could not
be estimated from this experiment because the maximal effect
was achieved at the lowest dose tested. The efﬁcacy of inhibi-
tion of TRADD expression for the high-dose group could not
be obtained, as the high-dose group of animals treated with
4b was sacriﬁced early due to severe toxicity observed as
discussed below. Mismatch control MOE and LNA ASOs
5a and 5b showed no reduction in mRNA, indicating a
speciﬁc in vivo antisense effect on the target mRNA.
LNA ASOs induce profound hepatotoxicity
As part of the routine monitoring of animals during the study,
plasma bilirubin and transaminase levels for all the high-dose
groups were examined at Day 8 of the study in order to assess
liver function. Bilirubin, ALT and AST levels were within the
normal range for all animals, except for the 2-14-2 LNA
ASOs 4b and 5b. LNA 4b showed elevations of 186-, 75-
and 18-fold for ALT, AST and bilirubin, respectively, relative
to saline treated animals. Notably, even the control LNA 5b,
which showed no TRADD mRNA reduction, showed 46- and
25-fold increases in ALT and AST, respectively. Prior to
receiving the fourth dose of ASO on Day 11 of the study,
all the animals in the 4.5 mmol/kg group receiving LNA
ASO 4b experienced signiﬁcant weight loss, losing  25%
of their body weight (Supplementary Figure S1). Because
of this severe weight loss, coupled with the very large
transaminase increases seen with 4b, the study was termi-
nated early for this dose group. Upon necropsy, these animals
showed severe hepatotoxicity by histopathological analysis,
discussed further below.
The ALT and AST levels for all the remaining groups
at the termination of study on Day 21 indicate a striking
difference in the liver function proﬁle of the MOE and LNA
ASOs (Figure 4). All LNA ASOs studied showed at least
a 10-fold increase in transaminases for the 4.5 mmol/kg
dose groups, and some showed increases of >100-fold such
as 3b, 4b (despite receiving only 3/6 doses) and 5b. In con-
trast, the transaminase levels in mice treated with MOE ASOs
were within the normal range. The observed hepatotoxicity
in the LNA ASO series was both compound and dose-
dependent, with ASOs having a larger DNA gap increasing
hepatotoxicity. Further evidence for the toxicity of the LNA
ASOs was evident from the organ weights (Supplementary
Figure S2). LNA ASOs produced large (45–62%, relative to
saline) liver weight increases in a dose-dependent manner,
except for 5b, which had a smaller (25%), non-dose-
dependent increase. In contrast, the MOE ASOs showed
much smaller (0–17%) liver weight increases. Increase in
spleen weight was more variable, with 2b and 3b producing
large (>100%, relative to saline) increases. The increase in
spleen weights could be a direct proinﬂammatory effect of
the oligonucleotide or secondary to the severe hepatotoxicity.
LNA ASOs induce apoptosis in vitro and in vivo
Examination of H&E stained liver sections from mice treated
with LNA ASOs 1b and 4b, as well as control oligo-
nucleotide 5b, conﬁrmed hepatotoxic events. Histopathological
observationsincludedsignsofapoptosis,profoundeosinophilic
cytoplasmic degeneration with glycogen depletion and
hyperchromatic nuclei, as well as centrilobular coagulative
necrosis surrounded with inﬂammatory inﬁltrate containing
neutrophils,monocytesandlymphocytes(Figure5).Lesionsof
intracytoplasmic microvesicular changes were also visualized
Figure 3. Reduction of TRADD mRNA for MOE (a series) and LNA (b series) ASOs. *Not Analyzed: due to severe toxicity at 8 days, the 4.5 mmol/kg dose
group of 4b was terminated early.
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signs of steatosis. An increased number of mitotic hepatocytes
werealsoobservedinliversectionsfromLNAtreated animals,
likely indicating regeneration of damaged tissue.
To further characterize the hepatotoxicity associated with
LNA ASO treatment, we conducted immunohistopathological
evaluation to characterize the type of toxicity observed
(Figure 5 and Supplementary Table S2). Liver sections
from animals treated with LNA ASOs were stained for the
expression of GADD45b, the activated form of caspase 3,
peroxisome membrane protein 70 and Bax. Increased expres-
sion of activated caspase 3 and Bax suggested increased
apoptosis in livers of LNA, but not MOE, oligonucleotide
treated mice. GADD45b is a p53 and NF-kB regulated
gene induced in response to cell stress. The LNA but not
MOE modiﬁed oligonucleotides increased GADD45b expres-
sion dramatically. Evidence of peroxisome proliferation was
also suggested by increased expression of peroxisome mem-
brane protein 70 by IHC. Increased staining of each of these
markers was dose-dependent and correlated well with ALT
increases. To further conﬁrm apoptosis involvement of liver
injury mediated by LNA, liver sections of saline and LNA
treated animals were stained with the monoclonal antibody
M30, which is an apoptosis marker that monitors the
neoantigen formed by caspase cleavage of cytokeratin 18.
M30immunoreactivecellsappearatanearlystageofapoptosis
in epithelial cells, and are not detectable in vital or necrotic
epithelial cells (40). Animals treated with LNA ASOs 1b, 4b
or 5b all showed greatly increased M30 staining relative to
saline treated animals (Figure 5), providing further evidence
for apoptosis induced by treatment with the LNA ASOs.
To examine whether LNA ASOs could induce apoptosis in
cell culture, we examined representative TRADD ASOs 2a,
4a at 300 nM in A549 cells for their ability to induce caspase
3 activity, a common marker of apoptosis, in cell culture
after transfection (35). The LNA ASOs 2b and 4b resulted
in a 3.1- and 6.2-fold induction of caspase 3 activity relative
to control ASO 12, respectively, whereas the corresponding
MOE ASOs gave no change relative to the control ASO
(Supplementary Figure S3).
LNA ASO improves potency but also increases toxicity
To verify the activity and toxicity observed with 4b,i t
was tested in a repeat set of experiments along with 1a as a
comparator (Figure 6). In addition to the previously utilized
doses of 4.5, 1.5 and 0.5 mmol/kg, we also examined 0.9,
0.3 and 0.1 mmol/kg doses of 4b in order to assess to what
Figure 4. Plasma transaminase levels for MOE (a series) and LNA (b series) ASOs. **Data from 8 days. AST 4020 ± 850, ALT 6470 ± 1450, and severe weight
loss led to early termination of 4.5 mmol/kg dose group of 4b.
Nucleic Acids Research, 2007, Vol. 35, No. 2 693Figure 5. Histopathology of liver sections from mice treated MOE (a series) and LNA (b series) ASOs at 4.5 mmol/kg twice weekly for 3 weeks. Livers from
animals treated with LNA ASOs 1b, 4b and 5b present with significant hepatotoxicities as demonstrated in (A), a routing H&E stain showing profound swollen
eosinophilic degeneration, cell death (right arrow) and hyperchromatic nuclei (up arrow) of hepatocytes. The immunohistochemistry reveals that the injured
hepatocytes appear with cytoplasmic staining (brown stain cells, up arrows) of cleavage caspase 3 (B), pro-apoptotic protein BAX (C) and M30 (D), a neo-
epitope generated in epithelial cells as a result of caspase activation (cleavage). In addition a DNA damage and repair associated protein GADD45b (E) and
peroxisome membrane protein PMP70 (Supporting Supplementary Figure S2) were both found to have increased cytoplasmic expression in LNA treated livers.
IgG control slides of all four IHC markers were negative (data not shown).
694 Nucleic Acids Research, 2007, Vol. 35, No. 2extent potency was increased, as well as whether there was an
increase in therapeutic index. In this experiment, mice treated
with three doses of 4b at 4.5 mmol/kg (at 11 days) showed
minimal weight loss, and the study was continued for the
course of six administrations. At termination of the study,
the animals treated with 4b had lost 10% of their body
weight, as opposed to a 10% gain in the control group (Sup-
plementary Figures S4 and S5). Furthermore, organ weights,
transaminase increases and histopathological observations
upon necropsy were consistent with the previous results,
with >50-fold increases in AST and ALT at the 1.5 and
4.5 mmol/kg dose levels. The target reduction for 4b observed
was similar to the ﬁrst experiment, with 70 ± 8, 76 ± 6 and
66 ± 8% reduction of TRADD mRNA at the 4.5, 1.5 and
0.5 mmol/kg doses, respectively. The 0.9 mmol/kg dose
( 5 mg/kg) produced the maximal effect of 4b, providing
an 81 ± 4% reduction of TRADD mRNA, but also appeared
to be above the maximum non-toxic dose, as transaminases
were increased  5-fold.
The 2-14-2 LNA 4b clearly demonstrated a dose-
dependent reduction of TRADD mRNA, with an ED50 of
 0.37 mmol/kg (corresponding to  2 mg/kg, Table 2). This
suggests an improvement in potency of  4–5-fold relative
to the corresponding 2-14-2 MOE 4a, and 6–7-fold relative
to the comparator 4-10-4 MOE gapmer 1a. At dosage levels
used for the previous study, the activity of 1a was essentially
identical to that observed previously. A higher dose of
6.2 mmol/kg ( 40 mg/kg) of 1a produced a larger reduction
(86 ± 3%) of TRADD mRNA. At all doses of 1a employed,
there was no evidence for toxicity as measured by
transaminase levels, organ weights, body weights or
histopathological analysis of liver tissue samples. Thus,
though LNA ASO 4b was more potent than the comparator
MOE ASOs, it was not more efﬁcacious, and furthermore
did not produce maximal efﬁcacy in the absence of observ-
able toxicity. These results demonstrate that despite the
increase in potency observed with the LNA ASOs, the thera-
peutic index is not increased, and is probably decreased relat-
ive to the corresponding MOE ASOs.
It is possible that both the improved potency and increased
toxicity could be due to increased distribution of LNA modi-
ﬁed oligonucleotides to liver. To determine if this was the
case, the concentration of ASO in the liver was measured
at the conclusion of the study for ASOs 1–4 (Table 2). The
repeat group of 4b treated animals was used for this analysis,
as the mice received the same number of total doses. The
liver concentrations ranged from a high of 116 mg/g for 1a
to a low of 48 mg/g for 4b. These results are consistent
with expectations of higher metabolic stability for ASOs
having greater numbers of MOE and LNA modiﬁcations,
and also with increased distribution to liver for ASOs having
more PS linkages. As the concentration trend of ASO in liver
does not correlate with potency or toxicity, the increased
potency and/or toxicity of LNA oligonucleotides is not due
to more accumulation in the liver.
LNA ASO 4b shows hepatotoxicity with a single
administration
To better characterize the nature of the hepatotoxicity, we
administered a single dose of either MOE ASO 1a or LNA
Figure 6. Transaminases (bar graph, left scale) and reduction of TRADD mRNA (points on line graph, right scale) after treatment with the 4-10-4 MOE gapmer
1a or the 2-14-2 LNA gapmer 4b.
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dosing. In addition to plasma transaminases and histopatho-
logy, levels of cleaved caspase 3 and phosphorylated eIF2a
(p-eIF2a) were examined by western blot. Phosphorylation
of eIF2a has been shown to mediate apoptosis, presumably
via the inhibition of translation (41). Additionally, levels of
Bax, GADD45b, PUMA, p53, TNFa and MDM2 mRNA
were evaluated by RT–PCR. For all groups except for the
12 mmol/kg dosage level of 4b, there was no discernable dif-
ference from saline for any measured endpoint. In contrast,
administration of 12 mmol/kg of the LNA ASO 4b gave a
7- and 2-fold elevation in ALT and AST, respectively, at
the day 4, but not at the day 2 time-point. Concurrent with
this increase in transaminases at day 4, an increase in
p-eIF2a was observed by western blot (Supplementary
Figure S6). No increases in other genes studied were evident
by RT–PCR or western blot. However, weak staining of acti-
vated caspase 3, Bax and the M30 neoantigen were observed
by immunohistochemistry (Supplementary Table S3). These
results indicate that the hepatotoxicity induced by LNA 4b
can occur in as little as 4 days, and are consistent with
acute liver injury caused by induction of apoptosis.
LNA effects on potency and hepatotoxicity are
independent of target
To help rule out a potential target related contribution to the
hepatotoxicity and to verify the improved potency for other
targets, we tested additional LNA ASOs targeting other
mouse genes. We have previously published data demonstrat-
ing speciﬁc reduction of mouse ApoB (19) and PTEN (18)
mRNA in mice treated with 20mer MOE ASOs. Three active
ASO sequences (6, 8 and 9, Table 1) targeting either mouse
ApoB or mouse PTEN were identiﬁed in cell culture assays
using methods previously described for these targets. Because
the LNA ASO design having two LNA nucleosides ﬂanking a
large deoxy gap region appeared to exhibit the greatest
increase in potency and hepatotoxicity, we utilized a 2-16-2
design, and applied it to the previously identiﬁed 5-10-5
MOE sequences.
For the ApoB target, ASOs were dosed at 2.5 and either
0.5 or 0.4 mmol/kg twice weekly for 3 weeks (Figure 7).
The 5-10-5 MOE ASO 6 produced a modest 24% inhibition
of ApoB mRNA at the 0.4 mmol/kg dose and an 84% inhibi-
tion at the 2.5 mmol/kg dose. The 2-16-2 MOE ASOs 7a
and 8a gave no inhibition at the low dose, and produced
 50% reduction in ApoB-100 mRNA at the 2.5 mmol/kg
( 18 mg/kg) dose. The potency increase of the LNA ASOs
was variable, with LNA 7b providing a 5-fold estimated
increase in potency over the corresponding 2-16-2 MOE 7a,
but not the parent 5-10-5 MOE ASO 6. LNA 8b was only
marginally more active than MOE 8a, and substantially
less active than the MOE 6. None of the MOE ASOs showed
evidence for toxicity as measured by organ weights and
serum transaminase increases. In contrast the LNA ASOs
7b and 8b both resulted in >20-fold increases in AST and
ALT, along with increased organ weights at the 2.5 mmol/
kg dose.
ASOs targeting murine PTEN were dosed at 0.083–
2.25 mmol/kg twice weekly for 3 weeks (Figure 8). The
parent MOE 5-10-5 ASO 9 as well as its gap widened coun-
terpart 10a reduce target mRNA in a dose-dependent manner
Figure 7. Transaminases (bar graph, left scale), and reduction of ApoB mRNA (points on line graph, right scale) after treatment with MOE (a series) and LNA
(b series) ASOs.
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levels, organ weights and body weights. The LNA ASO
10b was signiﬁcantly more potent (estimated 5–10-fold)
than either MOE ASO. However, once again, this increase
in potency correlated with an increase in hepatotoxicity.
The 0.75 mmol/kg dose group started to show mild transami-
nase elevations, while the higher dose group resulted in large
(>50-fold) increases in both AST and ALT, increases in liver
and spleen weights and caused signiﬁcant weight loss in trea-
ted animals. A non-targeted control 5-10-5 MOE ASO 12 had
no effect on either target or toxicity measures.
LNA ASO hepatotoxicity is not likely due to
LNA degradation products
To help determine if the increased toxicity of the LNA ASOs
was due to the oligonucleotide or to degradation products, we
prepared mixed backbone versions of the PTEN 2-16-2 ASOs
containing phosphodiester (PO) linkages between LNA
nucleosides as well as at the LNA/DNA junction (Table 1).
These ASOs are much more rapidly metabolized in vivo,
and presumably will release either free MOE or LNA nucleo-
sides or nucleotides. If these nucleosides or nucleotides were
the source of the observed hepatotoxicity, these ASOs should
be more toxic, while if the intact ASO was causing the
hepatotoxicity, the mixed backbone versions should be less
toxic. Neither the MOE (11a) nor LNA (11b) ASO caused
signiﬁcant target reduction at the doses tested. Importantly,
the LNA containing ASO showed no evidence of hepatotoxi-
city, and analysis of drug levels in liver conﬁrmed near com-
plete metabolism of the intact drug 11b. These results suggest
that the intact LNA oligonucleotides are responsible for the
observed hepatotoxicity.
LNA ASO shows hepatotoxicity in rats
As the sequence of the PTEN ASOs was homologous to
rat, we were able to examine if LNA 10b was more potent
in rat, and importantly if the toxicity observed in mouse trans-
lated to another species. Accordingly, rats were treated with
ASOs 9, 10b, or control 12 at dose of 0.83, 2.5 or
7.5 mmol/kg twice weekly for 3 weeks (Supplementary
Figures S7–S9). The MOE ASO 9 showed a dose-dependent
reduction of PTEN mRNA in rat liver, with an ED50 of
 2.5 mmol/kg. In contrast to the mouse data, the LNA
ASO 10b was only slightly more potent in rat liver, with
an estimated ED50 of  1.5 mmol/kg. However, the LNA
ASO was also hepatotoxic in rats. At the 7.5 mmol/kg dose,
body weights were decreased 25% relative to control ASO
12, AST (but not ALT) was increased 5- and 10-fold, respec-
tively in two of the four animals, and bilirubin was increased
dramatically in the same two animals. Histopathological
evaluation of H&E stained liver sections conﬁrmed hepato-
toxicity, showing moderate eosinophilic cytoplasmic degene-
ration with focal single cell apoptosis and mild mononuclear
cell inﬁltration (Supplementary Table S4). No hepatotoxicity
was observed by histopathological evaluation, ALT, AST,
bilirubin, organ weights or body weights for either of the
MOE ASOs. This data suggest that the potency increase of
LNA ASOs relative to MOE ASOs is more pronounced in
mouse than in rat, though the observed hepatotoxicity is
still present in rat.
DISCUSSION
The main goal of our study was to determine if LNA contain-
ing ASOs would improve potency and therapeutic index
Figure 8. Transaminases (bar graph, left scale), and reduction of PTEN mRNA (points on line graph, right scale) after treatment with MOE (a series) and LNA
(b series) ASOs.
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tion entering the work was that an improvement in potency
would yield an improved therapeutic index, since it has
been generally believed that many of the toxicities of ASOs
are due to class effects as a result of the PS backbone. How-
ever, this proved not to be the case with the LNA ASOs
studied.
Our results clearly demonstrate the ability to improve
potency with some, but not all, LNA containing ASO designs,
particularly for the TRADD and PTEN targets. This improve-
ment was occasionally fairly large, as much as 5–10-fold, and
was most pronounced for LNA ASOs of length 18–20 nt
which contained 2–3 LNA residues at each end. As little as
0.75–1 mmol/kg ( 5–6 mg/kg) of these ASOs given twice
weekly for 3 weeks reduced target mRNA by 80%. The opti-
mal LNA ASO design in vivo appeared to be different than
that observed in cell culture, where we found that two LNA
nucleotides on each end of the ASO provided the largest
potency increase. This is evident from a comparison of 3b
and 4b, where 3b was 5-fold more potent in cell culture,
but less potent in vivo. It is unlikely that the improved
potency is due solely to increased afﬁnity of the ASO for tar-
get RNA, as adding more LNA to the ASO actually decreased
potency both in cell culture and in vivo (compare 2b and 3b
with 1b). Because of these trends, combined with the lack of
increased distribution of LNA ASOs to liver, it is likely that
other factors are contributing to the increased potency of
LNA modiﬁed ASOs observed in our studies. Additional
investigations will be required to further characterize the
nature of this potency improvement.
Unfortunately, the increased activity of LNA containing
ASOs was also accompanied by the observation of severe
hepatotoxicity, such that there was little or no separation
between toxic doses and those that produced signiﬁcant
levels of mRNA reduction. Hepatotoxicity was chemistry-,
sequence- and design-dependent, as it was only observed
with LNA containing ASOs, and the onset occurred at
slightly different dose levels for different compounds. The
fact that the MOE ASOs in some cases (compare 2a with
2b, and 6 with 7b and 8b) produced similar reductions in tar-
get RNA without producing observable toxicity suggest that
the toxicity is not secondary to reduction in target gene
expression. This is further supported by the observation of
severe hepatotoxicity with control 5b, which has >3 mis-
matches to all known mouse sequences. Hepatotoxicity also
seemed to be the most severe for the more potent LNA
ASO designs regardless of target (see 4b, mismatch 5b, 7b
and 10b). Thus, therapeutic index was not improved, and
was likely decreased relative to the MOE ASOs.
The hepatotoxicity was evident from the observation of
multiple parameters, including histopathological evaluation
of liver tissue upon necropsy as well as large increases in
plasma levels of aminotransferases (ALT and AST). Further-
more, the toxicity was commonly accompanied by large
increases in liver and/or spleen weights, likely as a con-
sequence arising from a response to hepatic injury induced
by the LNA ASOs. In several cases, the toxicity was severe
enough to cause extensive weight loss in the animals. Histo-
logy data clearly demonstrated both LNA oligonucleotide-
indiced liver necrosis and activation of apoptosis pathways,
as evidenced by H&E staining, as well as cleaved caspase 3,
increased Bax expression and increased expression of the
M30 neo-epitope. The upregulation of the pro-apoptotic pro-
tein Bax suggests involvement of the p53-mediated apoptosis
pathway, as Bax is a key response gene to p53 activation
(42,43). Furthermore, GADD45b, a key downstream target
gene of p53 during DNA damage and repair process
(44), was highly up-regulated in the injured hepatocytes.
GADD45b appears to help protect cells against programmed
cell death through blocking the c-jun N-terminal kinase cas-
cade, and is probably induced in response to cellular damage.
It is unclear why LNA oligonucleotides cause this level of
hepatotoxicity though the corresponding MOE oligo-
nucleotides do not. One possibility is that antisense effects
on genes partially complementary to the hepatotoxic ASOs
are playing a role in the toxicity, as LNA ASOs have been
shown to decrease the selectivity for a perfectly complemen-
tary target relative to the corresponding MOE ASOs (45).
However, this seems unlikely because multiple unrelated
LNA sequences cause similar toxicities. All oligonucleotides
were prepared and puriﬁed in the same laboratory using the
identical methods. The impurity proﬁles of LNA and MOE
ASOs were nearly identical, and contained only the expected
impurities resulting from PS oligonucleotide synthesis (PO,
N-1, etc.). This makes it extremely unlikely that the toxicity
is due to impurities resulting from LNA, but not MOE
oligonucleotide synthesis. Additionally, since the metaboli-
cally unstable PO containing ASO 11b (which should be
metabolized in vivo to LNA nucleosides and nucleotides)
was non-toxic, it is not likely that the toxicity is due to the
LNA monomers. This suggests that the intact LNA contain-
ing PS oligonucleotides are responsible for the observed toxi-
city. There are distinct structural differences between MOE
and LNA which may allow LNA containing oligonucleotides
to selectively effect hepatotoxicity. Perhaps importantly, the
rigid acyclic 20-methoxyethyl side chain of MOE protects
the corresponding 30-phosphorothioate linkage from inter-
actions via increased steric bulk and hydration (8), relative
to the compact and more hydrophobic cyclic structure of
LNA. This could cause selective binding afﬁnity differences
between MOE and LNA oligonucleotides for as yet unknown
macromolecular binding partners, and/or result in differential
compartmentalization of the two classes of oligonucleotides
within liver tissue.
The mild hepatotoxicity induced 4 days after a single
administration of LNA ASO 4b occurred concurrently with
apoptosis and activation of Bax and caspase 3 in hepatocytes
as evidenced by histopathological evaluation. Furthermore,
an increase in p-eIF2a was observed to coincide with the
onset of toxicity. Phosphorylated eIF2a inhibits translation
initiation, and has been shown to mediate apoptosis,
possibly by preventing the synthesis of short lived anti-
apoptotic factors (41,46). There are four known kinases
which phosphorylate eIF2a: PKR, which is activated by
binding of double stranded RNA (dsRNA); GCN2, which is
activated by amino acid deprivation; HRI, which is activated
by low heme levels; and PERK, which responds to stress
in the endoplasmic reticulum. It is unclear from our data
how treatment with hepatotoxic LNA oligonucleotides
results in increased phosphorylation of eIF2a; however, it
is tempting to speculate that PKR could be involved. PKR
is activated by binding of dsRNA to distinct dsRNA binding
698 Nucleic Acids Research, 2007, Vol. 35, No. 2domains which serve as allosteric inhibitors of the kinase
domain (47,48). It remains to be determined if LNA oligo-
nucleotides interact with PKR, and more extensive mechanis-
tic work is required to conﬁrm both p-eIF2a mediation of an
acute apoptotic response in hepatocytes, and elucidate the
precise biochemical mechanism responsible for the observed
hepatotoxicity.
In conclusion, we have shown that optimization of size
and gap conﬁguration employing LNA containing ASOs
can improve potency in mouse liver. However, this potency
increase is strongly correlated with the onset of a severe
hepatotoxicity not seen with the corresponding MOE ASOs,
and therapeutic index is not improved. These results suggest
that while LNA ASOs have the potential to improve potency
of antisense therapeutics, they impose a signiﬁcant risk of
hepatotoxicity. The toxicities observed herein also pose chal-
lenges for interpreting target validation and pharmacology
experiments using LNA ASOs in rodent models. It is possible
more extensive screening efforts may identify less toxic LNA
sequences, or that other ASO designs utilizing LNA may not
elicit hepatotoxicity. Additionally, bicyclic nucleosides simi-
lar to LNA such as amino-LNA, thio-LNA (27) and ENA
(which contains one extra methylene unit in the bicyclic
bridge) (49) have been reported to show antisense effects
similar to LNA and MOE ASOs. Although optimized designs
of one or more of these modiﬁcations may ultimately improve
potency while maintaining the safety proﬁle of MOE ASOs,
no detailed characterization of their toxicological properties
has yet been reported. It is clear that additional structure–
activity and structure–toxicity relationship studies will be
required to more fully assess the therapeutic potential of
LNA and other bicyclic nucleoside modiﬁed oligo-
nucleotides. Ultimately, the value of LNA oligonucleotide
drugs will be determined in human clinical trials, where
they are currently being developed for the treatment of
cancer. Our results are based only on studies in rodents; how-
ever, caution should be exercised in the clinical development
of LNA modiﬁed oligonucleotides, especially for chronic,
non-life threatening indications.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors thank Charles Allerson, Amy Dan and Rick Carty
for synthesis of oligonucleotides, Megan Pearce for determi-
nation of ASO levels in liver tissue, Denis Drygin for the
caspase 3 activation data, Richard H. Griffey for numerous
thought provoking discussions and Stanley T. Crooke and
Arthur A. Levin for a critical read of the manuscript. Funding
to pay the Open Access publication charges for this article
was provided by Isis Pharmaceuticals.
Conflict of interest statement. None declared.
REFERENCES
1. Vitravene Study Group (2002) Randomized dose-comparison studies of
intravenous fomiversen for treatment of cytomegalovirus retinitis that
has reactivated or is persistently active despite other therapies in
patients with AIDS. Am. J. Ophthalmol., 133, 475–483.
2. Eckstein,F. (2000) Phosphorothioate oligodeoxynucleotides: what is
their origin and what is unique about them? Antisense Nucleic Acid
Drug Dev., 10, 117–121.
3. Stein,C.A., Subasinghe,C., Shinozuka,K. and Cohen,J.S. (1988)
Physicochemical properties of phosphorothioate
oligodeoxynucleotides. Nucleic Acids Res., 16, 3209–3221.
4. Geary,R.S., Yu,R.Z. and Levin,A.A. (2001) Pharmacokinetics of
phosphorothioate antisense oligodeoxynucleotides. Curr. Opin.
Investig. Drugs, 2, 562–573.
5. Lima,W.F., Nichols,J.G., Wu,H., Prakash,T.P., Migawa,M.T.,
Wyrzykiewicz,T.K., Bhat,B. and Crooke,S.T. (2004) Structural
requirements at the catalytic site of the heteroduplex substrate for
human RNase H1 catalysis. J. Biol. Chem., 279, 36317–36326.
6. Monia,B.P., Lesnik,E.A., Gonzalez,C., Lima,W.F., McGee,D.,
Guinosso,C.J., Kawasaki,A.M., Cook,P.D. and Freier,S.M. (1993)
Evaluation of 20-modified oligonucleotides containing 20-deoxy gaps as
antisense inhibitors of gene expression. J. Biol. Chem., 268,
14514–14522.
7. Martin,P. (1995) Ein neuer Zugang zu 2-O-Alkylribonucleosiden und
Eigenschaften deren Oligonucleotide. Helv. Chim. Acta, 78, 486–504.
8. Teplova,M., Minasov,G., Tereshko,V., Inamati,G.B., Cook,P.D.,
Manoharan,M. and Egli,M. (1999) Crystal structure and improved
antisense properties of 20-O-(2-methoxyethyl)-RNA. Nature Struct.
Biol., 6, 535–539.
9. McKay,R.A., Miraglia,L.J., Cummins,L.L., Owens,S.R., Sasmor,H.
and Dean,N.M. (1999) Characterization of a potent and specific class
of antisense oligonucleotide inhibitor of human protein kinase C-alpha
expression. J. Biol. Chem., 274, 1715–1722.
10. Altmann,K.H., Martin,P., Dean,N.M. and Monia,B.P. (1997) Second
generation antisense oligonucleotides—inhibition of pkc-alpha and
c-raf kinase expression by chimeric oligonucleotides incorporating
60-substituted carbocyclic nucleosides and 20-O-ethylene glycol
substituted ribonucleosides. Nucleosides Nucleotides, 16, 917–926.
11. Geary,R.S., Watanabe,T.A., Truong,L., Freier,S., Lesnik,E.A.,
Sioufi,N.B., Sasmor,H., Manoharan,M. and Levin,A.A. (2001)
Pharmacokinetic properties of 20-O-(2-methoxyethyl)-modified
oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther., 296,
890–897.
12. Yu,R.Z., Geary,R.S., Monteith,D.K., Matson,J., Truong,L., Fitchett,J.
and Levin,A.A. (2004) Tissue disposition of 20-O-(2-methoxy) ethyl
modified antisense oligonucleotides in monkeys. J. Pharm. Sci., 93,
48–59.
13. Geary,R.S., Yu,R.Z., Watanabe,T., Henry,S.P., Hardee,G.E.,
Chappell,A., Matson,J., Sasmor,H., Cummins,L. and Levin,A.A. (2003)
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate
20-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison
across species. Drug Metab. Dispos., 31, 1419–1428.
14. Zhang,H., Cook,J., Nickel,J., Yu,R., Stecker,K., Myers,K. and
Dean,N.M. (2000) Reduction of liver Fas expression by an
antisense oligonucleotide protects mice from fulminant hepatitis.
Nat. Biotechnol., 18, 862–867.
15. Yu,R.Z., Zhang,H., Geary,R.S., Graham,M., Masarjian,L.,
Lemonidis,K., Crooke,R., Dean,N.M. and Levin,A.A. (2001)
Pharmacokinetics and pharmacodynamics of an antisense
phosphorothioate oligonucleotide targeting Fas mRNA in mice.
J. Pharmacol. Exp. Ther., 296, 388–395.
16. Liang,Y., Osborne,M.C., Monia,B.P., Bhanot,S., Watts,L.M., She,P.,
Decarlo,S.O., Chen,X. and Demarest,K. (2005) Antisense
oligonucleotides targeted against glucocorticoid receptor reduce
hepatic glucose production and ameliorate hyperglycemia in diabetic
mice. Metabolism, 54, 848–855.
17. Zinker,B.A., Rondinone,C.M., Trevillyan,J.M., Gum,R.J., Clampit,J.E.,
Waring,J.F., Xie,N., Wilcox,D., Jacobson,P., Frost,L. et al. (2002)
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes
blood glucose, and improves insulin sensitivity in diabetic mice.
Proc. Natl Acad. Sci. USA, 99, 11357–11362.
18. Butler,M., McKay,R.A., Popoff,I.J., Gaarde,W.A., Witchell,D.,
Murray,S.F., Dean,N.M., Bhanot,S. and Monia,B.P. (2002) Specific
inhibition of PTEN expression reverses hyperglycemia in diabetic
mice. Diabetes, 51, 1028–1034.
19. Crooke,R.M., Graham,M.J., Lemonidis,K.M., Whipple,C.P., Koo,S.
and Perera,R.J. (2005) An apolipoprotein B antisense oligonucleotide
Nucleic Acids Research, 2007, Vol. 35, No. 2 699lowers LDL cholesterol in hyperlipidemic mice without causing
hepatic steatosis. J. Lipid Res., 46, 872–884.
20. Kastelein,J.J.P., Wedel,M.K., Baker,B.F., Su,J., Bradley,J.D., Yu,R.Z.,
Chuang,E., Graham,M.J. and Crooke,R.M. (2006) Potent reduction of
apolipoprotein B and LDL cholesterol by short-term administration of
an antisense inhibitor of apolipoprotein B. Circulation, 114,
1729–1735.
21. Chi,K.N., Eisenhauer,E., Fazli,L., Jones,E.C., Goldenberg,S.L.,
Powers,J., Tu,D. and Gleave,M.E. (2005) A phase I pharmacokinetic
and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense
oligonucleotide to clusterin, in patients with localized prostate cancer.
J. Natl Cancer Inst., 97, 1287–1296.
22. Sewell,K.L., Geary,R.S., Baker,B.F., Glover,J.M., Mant,T.G., Yu,R.Z.,
Tami,J.A. and Dorr,F.A. (2002) Phase I trial of ISIS 104838, a
20-methoxyethyl modified antisense oligonucleotide targeting tumor
necrosis factor-alpha. J. Pharmacol. Exp. Ther., 303, 1334–1343.
23. Obika,S., Nanbu,D., Hari,Y., Morio,K.-I., In,Y., Ishida,T. and
Imanishi,T. (1997) Synthesis of 20-O-40-C-methyleneuridine
and -cytidine. Novel bicyclic nucleosides having a fixed C30-endo
sugar puckering. Tetrahedron Lett., 38, 8735–8738.
24. Obika,S., Nanbu,D., Hari,Y., Andoh,J.-I., Morio,K.-I., Doi,T. and
Imanishi,T. (1998) Stability and structural features of the duplexes
containing nucleoside analogs with a fixed N-type conformation,
20-O-40-C-methyleneribonucleosides. Tetrahedron Lett., 39,
5401–5404.
25. Wengel,J. (1999) Synthesis of 30-C- and 40-C-branched
oligodeoxynucleotides and the development of locked nucleic acid
(LNA). Acc. Chem. Res., 32, 301–310.
26. Koshkin,A.A., Nielsen,P., Meldgaard,M., Rajwanshi,V.K., Singh,S.K.
and Wengel,J. (1998) LNA (locked nucleic acid): an RNA mimic
forming exceedingly stable LNA:LNA duplexes. J. Am. Chem. Soc.,
120, 13252–13253.
27. Fluiter,K., Frieden,M., Vreijling,J., Rosenbohm,C., De Wissel,M.B.,
Christensen,S.M., Koch,T., Orum,H. and Baas,F. (2005) On the in vitro
and in vivo properties of four locked nucleic acid nucleotides
incorporated into an anti-H-Ras antisense oligonucleotide. Chem.
Biochem, 6, 1104–1109.
28. Siwkowski,A.M., Madge,L.A., Koo,S., McMillan,E.L., Monia,B.P.,
Pober,J.S. and Baker,B.F. (2004) Effects of antisense
oligonucleotide-mediated depletion of tumor necrosis factor (TNF)
receptor 1-associated death domain protein on TNF-induced gene
expression. Mol. Pharmacol., 66, 572–579.
29. Chiang,M.Y., Chan,H., Zounes,M.A., Freier,S.M., Lima,W.F. and
Bennett,C.F. (1991) Antisense oligonucleotides inhibit intercellular
adhesion molecule 1 expression by two distinct mechanisms.
J. Biol. Chem., 266, 18162–18171.
30. Dean,N.M. and McKay,R. (1994) Inhibition of protein kinase C-alpha
expression in mice after systemic administration of phosphorothioate
antisense oligodeoxynucleotides. Proc. Natl Acad. Sci. USA, 91,
11762–11766.
31. Vickers,T.A., Koo,S., Bennett,C.F., Crooke,S.T., Dean,N.M. and
Baker,B.F. (2003) efficient reduction of target RNAs by small
interfering RNA and RNase H-dependent antisense agents.
J. Biol. Chem., 278, 7108–7118.
32. Ross,B. and Song,Q. (2004) US U.S. Pat. Appl. Publ. 20040082775.
33. Ross,B.S., Song,Q. and Han,M. (2005) Kilo-scale synthesis process for
20-O-(2-methoxyethyl)-pyrimidine derivatives. Nucleosides
Nucleotides Nucleic Acids, 24, 815–818.
34. Ravikumar,V.T., Andrade,M., Carty,R.L., Dan,A. and Barone,S. (2006)
Development of siRNA for therapeutics: efficient synthesis of
phosphorothioate RNA utilizing phenylacetyl disulfide (PADS).
Bioorg. Med. Chem. Lett., 16, 2513–2517.
35. Drygin,D., Barone,S. and Bennett,C.F. (2004) Sequence-dependent
cytotoxicity of second-generation oligonucleotides. Nucluic Acids Res.,
32, 6585–6594.
36. Leeds,J.M., Graham,M.J., Truong,L. and Cummins,L.L. (1996)
Quantitation of phosphorothioate oligonucleotides in human plasma.
Anal. Biochem., 235, 36–43.
37. Frieden,M., Christensen,S.M., Mikkelsen,N.D., Rosenbohm,C.,
Thrue,C.A., Westergaard,M., Hansen,H.F., Orum,H. and Koch,T.
(2003) Expanding the design horizon of antisense oligonucleotides with
alpha-l-LNA. Nucleic Acids Res., 31, 6365–6372.
38. Wu,H., Lima,W.F., Zhang,H., Fan,A., Sun,H. and Crooke,S.T. (2004)
Determination of the role of the human RNase H1 in the pharmacology
of DNA-like antisense drugs. J. Biol. Chem., 279, 17181–17189.
39. Bondensgaard,K., Petersen,M., Singh,S.K., Rajwanshi,V.K., Kumar,R.,
Wengel,J. and Jacobsen,J.P. (2000) Structural studies of LNA:RNA
duplexes by NMR: conformations and implications for RNase H
activity. Chem.-Eur. J., 6, 2687–2695.
40. Grassi,A., Susca,M., Ferri,S., Gabusi,E., D’Errico,A., Farina,G.,
Maccariello,S., Zauli,D., Bianchi,F.B. and Ballardini,G. (2004)
Detection of the M30 neoepitope as a new tool to quantify liver
apoptosis: timing and patterns of positivity on frozen and
paraffin-embedded sections. Am. J. Clin. Pathol., 121,
211–219.
41. Scheuner,D., Patel,R., Wang,F., Lee,K., Kumar,K., Wu,J., Nilsson,A.,
Karin,M. and Kaufman,R.J. (2006) Double-stranded RNA-dependent
protein kinase phosphorylation of the alpha-subunit of eukaryotic
translation initiation factor 2 mediates apoptosis. J. Biol. Chem., 281,
21458–21468.
42. Chipuk,J.E., Kuwana,T., Bouchier-Hayes,L., Droin,N.M.,
Newmeyer,D.D., Schuler,M. and Green,D.R. (2004) Direct activation
of Bax by p53 mediates mitochondrial membrane permeabilization and
apoptosis. Science, 303, 1010–1014.
43. Mihara,M., Erster,S., Zaika,A., Petrenko,O., Chittenden,T., Pancoska,P.
and Moll,U.M. (2003) p53 has a direct apoptogenic role at the
mitochondria. Mol. Cell, 11, 577–590.
44. Xiao,G., Chicas,A., Olivier,M., Taya,Y., Tyagi,S., Kramer,F.R. and
Bargonetti,J. (2000) A DNA damage signal is required for p53 to
activate gadd45. Cancer Res., 60, 1711–1719.
45. Simoes-Wust,A.P., Hopkins-Donaldson,S., Sigrist,B., Belyanskaya,L.,
Stahel,R.A. and Zangemeister-Wittke,U. (2004) A functionally
improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2
and Bcl-xL expression and facilitates tumor cell apoptosis.
Oligonucleotides, 14, 199–209.
46. Saelens,X., Kalai,M. and Vandenabeele,P. (2001) Translation
inhibition in apoptosis: caspase-dependent PKR activation and
eIF2-alpha phosphorylation. J. Biol. Chem., 276, 41620–41628.
47. Nanduri,S., Rahman,F., Williams,B.R. and Qin,J. (2000) A
dynamically tuned double-stranded RNA binding mechanism for the
activation of antiviral kinase PKR. EMBO J., 19, 5567–5574.
48. Wu,S. and Kaufman,R.J. (1997) A model for the double-stranded RNA
(dsRNA)-dependent dimerization and activation of the
dsRNA-activated protein kinase PKR. J. Biol. Chem., 272,
1291–1296.
49. Koizumi,M., Takagi-Sato,M., Okuyama,R., Araki,K., Sun,W.,
Nakai,D., Tsutsumi,S. and Kawai,K. (2006) Direct comparison of
in vivo antisense activity of ENA oligonucleotides targeting PTP1B
mRNA with that of 20-O-(2-methoxy)ethyl-modified oligonucleotides.
Oligonucleotides, 16, 253–262.
700 Nucleic Acids Research, 2007, Vol. 35, No. 2